Atea Pharmaceuticals has reported positive interim data from the Phase II study where its antiviral drug candidate, AT-527, reduced viral load levels in mild-to-moderate Covid-19 patients in the hospital setting.

Co-developed by Atea and Roche, AT-527 is an oral direct-acting antiviral (DAA) agent.

The global, randomised, double-blind, placebo-controlled, multi-centre Phase II trial is analysing the safety, tolerability, clinical and antiviral efficacy of AT-527 in moderate Covid-19 patients.

Within five days of onset of symptoms, the trial subjects were given a twice-daily dose of either AT-527 550mg or placebo for five days.

The interim analysis included findings from 70 high-risk subjects hospitalised with Covid-19, of which 62 were evaluable for virology assessment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Data showed that AT-527 quickly decreased viral load levels and subjects in the treatment group had an 80% improved mean reduction from baseline viral load versus placebo at day two.

Furthermore, a sustained difference in a drop in viral load levels was maintained till the eighth day.

Nearly 47% of subjects in the AT-527 group and 22% in the placebo arm showed no detectable ribonucleic acid virus by day 14.

In addition, the oral drug was observed to be safe and well-tolerated, which is in line with earlier studies.

No serious adverse events or new safety risks linked to AT-527 were noted in the trial.

Atea Pharmaceuticals founder and CEO Jean-Pierre Sommadossi said: “We are very pleased with the potent antiviral activity of AT-527 demonstrated by the rapid inhibition of SARS-CoV-2 replication.

“Such potent activity may lead to faster recovery time for patients with Covid-19 while minimising the transmission of infection.”

Atea and Roche are currently studying AT-527 in the Phase III MORNINGSKY trial and Phase II MOONSONG virology study in mild or moderate Covid-19 patients in an outpatient setting.

Multi-cohort data from the MOONSONG study is anticipated in the third quarter of this year.